- Home
- NERV vs BCG Comparison
NERV vs BCG Comparison
Compare NERV & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NERV | BCG |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 29.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | NERV | BCG |
|---|---|---|
| Price | $3.97 | $2.36 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 40.4K | ★ 46.9K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $178,203,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $63.27 |
| Revenue Growth | N/A | ★ 10.19 |
| 52 Week Low | $1.15 | $1.36 |
| 52 Week High | $12.46 | $6.00 |
Technical Indicators
Market Signals| Indicator | NERV | BCG |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 52.74 |
| Support Level | $3.70 | $2.10 |
| Resistance Level | $4.07 | $2.37 |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 62.37 | 36.16 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.